



# Molina Healthcare of Michigan Synagis Prior Authorization Form

Phone: (855) 322-4077

Fax: (888) 373-3059

**Please make copies for future use.**

Date:	Patient DOB:
Pt. Name:	Patient Gestational Age at Birth:
Pt. Medicaid ID#:	Provider Phone:
Provider Name:	Provider Address:
Provider Phone:	Provider Fax:

Molina Healthcare authorizes Synagis™ (palivizumab) based on American Academy of Pediatrics (AAP) criteria. A Molina Preferred Specialty Pharmacy will be performing enrollment functions once treatment authorization is given by Molina. Synagis™ will in turn be shipped by the Specialty Pharmacy. If you have questions about Synagis™ distribution, please call Molina at 1-855-322-4077. The timing of season will be determined by annual virology reporting, but typically runs October 1 to May 1. For qualifying infants born during the RSV season, the total number of doses allowed during the season may vary. *A maximum of 5 doses will be approved per member per RSV season.*

**For dose requests outside of above season, provider must submit:**

Letter of medical necessity (LMN)

Current local virology information showing virology > 10% for most recent two consecutive weeks

**Please note how the patient meets AAP criteria below and include:**

Medical documentation supporting selection below

Documentation of patient's Gestational Age at birth

**Inclusion criteria**

Infants who are younger than 12 months of age at the start of the RSV season and are born before 29 weeks, 0 days' gestation.

Infants who are younger than 12 months of age who develop CLD of prematurity (defined as gestational age <32 weeks, 0 days) and required >21% oxygen for at least the first 28 days after birth.

Infants between 12 and 24 months of age who developed CLD of prematurity as defined above and who continue to require medical support (chronic corticosteroid therapy, diuretic therapy, supplemental oxygen or bronchodilator therapy) within 6 months of the start of RSV season.

Infants who are younger than 12 months of age with hemodynamically significant CHD as evidenced by:

- o acyanotic heart disease and are receiving medication to control congestive heart failure, and will require cardiac surgical procedures; or
- o moderate to severe pulmonary hypertension; or
- o cyanotic heart disease and Synagis is being recommended by a pediatric cardiologist

Children younger than 24 months who will undergo cardiac transplantation during the RSV season.

Children younger than 24 months who will be profoundly immunocompromised during the RSV season due to chemotherapy or other conditions

Infants who are younger than 12 months of age with neuromuscular disease, congenital anomalies of the airway or pulmonary abnormalities that impair the ability to clear secretions from the upper airway.

**Please note the following:**

Clinicians may administer up to a maximum of 5 monthly doses of palivizumab (15 mg/kg per dose) during the RSV season to infants who qualify for prophylaxis in the first year of life.

Monthly prophylaxis should be discontinued in any child who experiences a breakthrough RSV hospitalization.

Routine palivizumab prophylaxis for children with cystic fibrosis or Down syndrome is not recommended in the absence of the other qualifying indications listed above.